Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism

European Journal of Endocrinology

Volumn 169, Issue 5, 2013, Pages

  Lefebvre, H ^a,b,c   Prevost G ^a,b,c   Louiset, E ^a,b  

^a INSERM   (France)

^b UNIVERSITY OF ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ADRENOMEDULLIN; ALDOSTERONE; ANGIOTENSIN II; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE MORPHOGENETIC PROTEIN; CATECHOLAMINE; CORTICOSTEROID; CORTICOTROPIN; CYTOKINE; ENDOTHELIN; HYDROCORTISONE; INHIBIN; KETOCONAZOLE; METYRAPONE; MINERALOCORTICOID; MITOTANE; SEROTONIN; SEROTONIN 4 RECEPTOR; SOMATOMEDIN B; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA;

ADIPOCYTE; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX HYPERFUNCTION; ADRENAL CORTEX TUMOR; ADRENAL HYPERPLASIA; ADRENAL INCIDENTALOMA; AUTOCRINE EFFECT; BLOOD TOXICITY; CHROMAFFIN CELL; CORTICOSTEROID RELEASE; CUSHING SYNDROME; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERCORTISOLISM; LIVER TOXICITY; METABOLIC DISORDER; MYELOLIPOMA; NEUROTOXICITY; PARACRINE SIGNALING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STEROIDOGENESIS; TUMOR VASCULARIZATION;

ADRENAL CORTEX HORMONES; ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL HYPERFUNCTION; AUTOCRINE COMMUNICATION; HUMANS; PARACRINE COMMUNICATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84886298056     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0308     Document Type: Review

References (262)

1. Lacroix A, Baldacchino V, Bourdeau I, Hamet P & Tremblay J. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends in Endocrinology and Metabolism 2004 15 375-382.
2. Bornstein SR, Gonzalez-Hernandez JA, Ehrhart-Bornstein M, Adler G & Scherbaum WA. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. Journal of Clinical Endocrinology and Metabolism 1994 78 225-232. (doi:10.1210/jc.78.1.225)
3. Dorovini-Zis K & Zis AP. Innervation of the zona fasciculata of the adult human adrenal cortex: a light and electron microscopic study. Journal of Neural Transmission. General Section 1991 84 75-84. (doi:10.1007/BF01249111)
4. Engeland WC. Functional innervation of the adrenal cortex by the splanchnic nerve. Hormone and Metabolic Research 1998 30 311-314. (doi:10.1055/s-2007-978890)
5. Li Q, Johansson H & Grimelius L. Innervation of human adrenal gland and adrenal cortical lesions. Virchows Archiv 1999 435 580-589. (doi:10.1007/s004280050444)
6. Lefebvre H, Contesse V, Delarue C, Feuilloley M, Hery F, Grise P, Raynaud G, Verhofstad AA, Wolf LM & Vaudry H. Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin 4 receptor subtype. Neuroscience 1992 47 999-1007. (doi:10.1016/0306-4522(92)90047-6)
7. Lefebvre H, Compagnon P, Contesse V, Delarue C, Thuillez C, Vaudry H & Kuhn JM. Production and metabolism of serotonin (5-HT) by the human adrenal cortex: paracrine stimulation of aldosterone secretion by 5-HT. Journal of Clinical Endocrinology and Metabolism 2001 86 5001-5007. (doi:10.1210/jc.86. 10.5001)
8. Marx C, Bornstein SR, Wolkersdörfer GW, Peter M, Sippell WG & Scherbaum WA. Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. Journal of Clinical Endocrinology and Metabolism 1997 82 3136-3140. (doi:10.1210/jc.82.9.3136)
9. Marx C, Bornstein SR & Wolkersdörfer GW. Cellular immune-endocrine interaction in adrenocortical tissues. European Journal of Clinical Investigation 2000 30 (Suppl 3) 1-5. (doi:10.1046/j.1365-2362.2000. 0300s3001.x)
10. Bornstein SR, Rutkowski H & Vrezas I. Cytokines and steroidogenesis. Molecular and Cellular Endocrinology 2004 215 135-141. (doi:10.1016/j.mce.2003. 11.022)
11. Bassett JR & West SH. Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. Microscopy Research and Technique 1997 36 546-557. (doi:10.1002/(SICI)1097-0029(19970315) 36:6<546::AID-JEMT11>3.0.CO;2-O)
12. Sasano H, Ohashi Y, Suzuki T & Nagura H. Vascularity in human adrenal cortex. Modern Pathology 1998 11 329-333.
13. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, ScherbaumWA & Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. PNAS 2003 100 14211-14216. (doi:10.1073/pnas.2336140100)
14. Nussdorfer GG. Paracrine control of adrenal cortical function by medullary chromaffin cells. Pharmacological Reviews 1996 48 495-530.
15. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, ScherbaumWA & Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocrine Reviews 1998 19 101-143. (doi:10.1210/er.19.2.101)
16. Hinson JP & Kapas S. The role of endothelial cell products in the regulation of adrenocortical function: actions of endothelin, nitric oxide, adrenomedullin and PAMP. Hormone and Metabolic Research 1998 30 334-340. (doi:10.1055/s-2007-978894)
17. Takahashi K, Totsune K & Murakami O. Adrenocortical peptides: autocrine or paracrine regulators for the steroid hormone secretion or the cell proliferation? Experimental and Clinical Endocrinology and Diabetes 2002 110 373-380. (doi:10.1055/s-2002-36423)
18. Bornstein SR, Engeland WC, Ehrhart-Bornstein M & Herman JP. Dissociation of ACTH and glucocorticoids. Trends in Endocrinology and Metabolism 2008 19 175-180. (doi:10.1016/j.tem.2008.01.009)
19. Haase M, Willenberg HS & Bornstein SR. Update on the corticomedullary interaction in the adrenal gland. Endocrine Development 2011 20 28-37. (doi:10.1159/000321211)
20. Aguilera G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. Journal of Steroid Biochemistry and Molecular Biology 1993 45 147-151. (doi:10.1016/0960-0760(93)90134-I)
21. Pivonello R, Ferone D, de HerderWW, de Krijger RR,Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 4493-4502. (doi:10.1210/jc.2003-031746)
22. Kempná P, Körner M, Waser B, Hofer G, Nuoffer JM, Reubi JC & Flück CE. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Molecular and Cellular Endocrinology 2010 314 101-109. (doi:10.1016/j.mce.2009.08.010)
23. Rebuffat P, Forneris ML, Aragona F, Ziolkowska A, Malendowicz LK & Nussdorfer GG. Adrenomedullin and its receptors are expressed in the zona glomerulosa of human adrenal gland: evidence that ADM enhances proliferation and decreases apoptosis in cultured ZG cells. International Journal of Molecular Medicine 2002 9 119-124.
24. Ehrhart-Bornstein M, Bornstein SR & Scherbaum WA. Sympathoadrenal system and immune system in the regulation of adrenocortical function. European Journal of Endocrinology 1996 135 19-26. (doi:10.1530/eje.0.1350019)
25. Buijs RM,Wortel J, Van Heerikhuize JJ, Feenstra MG, Ter Horst GJ, Romijn HJ & Kalsbeek A. Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. European Journal of Neuroscience 1999 11 1535-1544. (doi:10.1046/j.1460-9568.1999.00575.x)
26. Ishida A, Mutoh T, Ueyama T, Bando H, Masubuchi S, Nakahara D, Tsujimoto G & Okamura H. Light activates the adrenal gland: timing of gene expression and glucocorticoid release. Cell Metabolism 2005 2 297-307. (doi:10.1016/j.cmet. 2005.09.009)
27. Clow A, Hucklebridge F, Stalder T, Evans P & Thorn L. The cortisol awakening response: more than a measure of HPA axis function. Neuroscience & Biobehavioral Reviews 2010 35 97-103. (doi:10.1016/j.neubiorev.2009.12.011)
28. Wolkersdörfer GW, Lohmann T, Marx C, Schröder S, Pfeiffer R, Stahl HD, Scherbaum WA, Chrousos GP & Bornstein SR. Lymphocytes stimulate dehydroepiandrosterone production through direct cellular contact with adrenal zona reticularis cells: a novel mechanism of immune-endocrine interaction. Journal of Clinical Endocrinology and Metabolism 1999 84 4220-4227. (doi:10.1210/jc.84.11.4220)
29. Oates EL, Allaway GP, Armstrong GR, Boyajian RA, Kehrl JH & Prabhakar BS. Human lymphocytes produce pro-opiomelanocortin gene-related transcripts. Effects of lymphotropic viruses. Journal of Biological Chemistry 1988 263 10041-10044.
30. Gonzalez-Hernandez JA, Bornstein SR, Ehrhart-Bornstein M, Späth-Schwalbe E, Jirikowski G & Scherbaum WA. Interleukin-6 messenger ribonucleic acid expression in human adrenal gland in vivo: new clue to a paracrine or autocrine regulation of adrenal function. Journal of Clinical Endocrinology and Metabolism 1994 79 1492-1497. (doi:10.1210/jc.79.5.1492)
31. González-Hernández JA, Bornstein SR, Ehrhart-Bornstein M, Gschwend JE, Gwosdow A, Jirikowski G & Scherbaum WA. IL-1 is expressed in human adrenal gland in vivo. Possible role in a local immune-adrenal axis. Clinical and Experimental Immunology 1995 99 137-141. (doi:10.1111/j.1365-2249. 1995.tb03484.x)
32. González-Hernández JA, Ehrhart-Bornstein M, Späth- Schwalbe E, Scherbaum WA & Bornstein SR. Human adrenal cells express tumor necrosis factor-A messenger ribonucleic acid: evidence for paracrine control of adrenal function. Journal of Clinical Endocrinology and Metabolism 1996 81 807-813. (doi:10.1210/jc.81.2.807)
33. Metcalfe DD. Mast cells and mastocytosis. Blood 2008 112 946-956. (doi:10.1182/blood-2007-11-078097)
34. Lefebvre H, Contesse V, Delarue C, Soubrane C, Legrand A, Kuhn JM, Wolf LM & Vaudry H. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism1993 77 1662-1666. (doi:10.1210/jc.77.6.1662)
35. Duparc C, Moreau L, Golib F, Boulkroun S, Benecke A, Gobet F, Meatchi T, Plouin P-F, Zennaro M-C, Louiset E et al. Potential role of intraadrenal mast cells in the physiopathology of aldosterone-producing adenoma. In ENDO 2012. Houston, Texas, USA, 2012.
36. Rossi GP, Andreis PG, Colonna S, Albertin G, Aragona F, Belloni AS & Nussdorfer GG. Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. Journal of Clinical Endocrinology and Metabolism 2002 87 322-328. (doi:10.1210/jc.87.1.322)
37. Rossi GP, Ganzaroli C, Cesari M, Maresca A, Plebani M, Nussdorfer GG & Pessina AC. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovascular Research 2003 57 277-283. (doi:10.1016/S0008- 6363(02)00658-2)
38. Ansurudeen I, Kopprasch S, Ehrhart-Bornstein M, Bornstein SR & Willenberg HS. Endothelial cell-mediated regulation of aldosterone release from human adrenocortical cells. Molecular and Cellular Endocrinology 2007 265-266 150-156. (doi:10.1016/j.mce.2006.12.011)
39. Hinson JP, Vinson GP, Kapas S & Teja R. The relationship between adrenal vascular events and steroid secretion: the role of mast cells and endothelin. Journal of Steroid Biochemistry and Molecular Biology 1991 40 381-389. (doi:10.1016/0960-0760(91)90205-J)
40. Krug AW, Vleugels K, Schinner S, Lamounier-Zepter V, Ziegler CG, Bornstein SR & Ehrhart-Bornstein M. Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. International Journal of Obesity 2007 311 605-616.
41. Vleugels K, Schinner S, Krause D, Morawietz H, Bornstein SR, Ehrhart-Bornstein M & Krug AW. ERK1/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokinemediated aldosterone secretion. Experimental and Clinical Endocrinology and Diabetes 2011 119 644-648. (doi:10.1055/s-0031-1284367)
42. Goodfriend TL, Egan BM & Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins, Leukotrienes and Essential Fatty Acids 1999 60 401-405. (doi:10.1016/S0952- 3278(99)80020-9)
43. Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A, Rosano GM & Caprio M. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Molecular and Cellular Endocrinology 2012 350 281-288. (doi:10.1016/j.mce.2011.09.011)
44. Ribeiro TC & Latronico AC. Insulin-like growth factor system on adrenocortical tumorigenesis. Molecular and Cellular Endocrinology 2012 351 96-100. (doi:10.1016/j.mce.2011.09.042)
45. Hofland J & De Jong FH. Inhibins and activins: their roles in the adrenal gland and the development of adrenocortical tumors. Molecular and Cellular Endocrinology 2012 359 92-100. (doi:10.1016/j.mce.2011.06.005)
46. Peters J. Local renin-angiotensin systems in the adrenal gland. Peptides 2012 34 427-432. (doi:10.1016/j.peptides.2012.01.023)
47. Gordon RD, Bachmann AW, Klemm SA, Tunny TJ, Stowasser M, Storie WJ & Rutherford JC. An association of primary aldosteronism and adrenaline-secreting phaeochromocytoma. Clinical and Experimental Pharmacology and Physiology 1994 21 219-222. (doi:10.1111/j.1440-1681.1994.tb02500.x)
48. Rogoff D, Bergada I, Venara M, Chemes H, Heinrich JJ & Barontini M. Intermittent hyperaldosteronism in a child due to an adrenal adenoma. European Journal of Pediatrics 2001 160 114-116. (doi:10.1007/s004310000654)
49. Inoue J, Oishi S, Naomi S, Umeda T & Sato T. Pheochromocytoma associated with adrenocortical adenoma: case report and literature review. Endocrinologia Japonica 1986 33 67-74. (doi:10.1507/endocrj1954.33.67)
50. Yoshioka M, Saito H, Kawakami Y, Mineyama H & Sekiya M. Adrenomedullary hyperplasia associated with cortisol producing adenoma. Endocrine Journal 1993 40 467-471. (doi:10.1507/endocrj.40.467)
51. Erem C, Hacihasanoglu A, Ersöz HO, Reis AK, Calik A, Ukinç K & Koçak M. Pheochromocytoma combined with pre-clinical Cushing's syndrome in the same adrenal gland. Journal of Endocrinological Investigation 2005 28 561-565.
52. Ghander C, Tenenbaum F, Tissier F, Silvera S, Lalej D, Dousset B & Groussin L. When adrenal Cushing's and phaeochromocytoma meet. Lancet 2012 380 1683. (doi:10.1016/S0140-6736(12)60438-3)
53. Takizawa N, Muguruma K & Sasano H. Pheochromocytoma and subclinical Cushing's syndrome with focal adrenocortical hyperplasia. International Journal of Urology 2011 18 548-549. (doi:10.1111/j.1442-2042.2011.02759.x)
54. Aiba M, Hirayama A, Iri H, Kodama T, Fujimoto Y, Kusakabe K, Akama H, Murai M & Tazaki H. Primary adrenocortical micronodular dysplasia: enzyme histochemical and ultrastructural studies of two cases with a review of the literature. Human Pathology 1990 21 503-511. (doi:10.1016/0046-8177(90)90006-Q)
55. Sahut-Barnola I, de Joussineau C, Val P, Lambert-Langlais S, Damon C, Lefrançois-Martinez AM, Pointud JC, Marceau G, Sapin V, Tissier F et al. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genetics 2010 6 e1000980. (doi:10.1371/journal.pgen. 1000980)
56. Wieneke JA, Thompson LD & Heffess CS. Corticomedullary mixed tumor of the adrenal gland. Annals of Diagnostic Pathology 2001 5 304-308. (doi:10.1053/adpa.2001.28297)
57. Alexandraki KI, Michail OP, Nonni A, Diamantis D, Giannopoulou I, Kaltsas GA, Tseleni-Balafouta S, Syriou V & Michail PO. Corticomedullary mixed adrenal tumor: case report and literature review. Endocrine Journal 2009 56 817-824. (doi:10.1507/endocrj.K09E-010)
58. Lau SK, Chu PG & Weiss LM. Mixed cortical adenoma and composite pheochromocytoma-ganglioneuroma: an unusual corticomedullary tumor of the adrenal gland. Annals of Diagnostic Pathology 2011 15 185-189. (doi:10.1016/j.anndiagpath.2010.02.005)
59. Donatini G, Van Slycke S, Aubert S & Carnaille B. Corticomedullary mixed tumor of the adrenal gland - a clinical and pathological chameleon: case report and review of literature. Updates in Surgery 2013 65 161-164. (doi:10.1007/s13304-011-0132-1)
60. Kaneko T, Matsushima H & Homma Y. Dopamine-secreting corticomedullary mixed tumor of the adrenal gland. International Journal of Urology 2012 19 1123-1124. (doi:10.1111/j.1442-2042.2012.03107.x)
61. Perraudin V, Delarue C, Lefebvre H, Do Rego J-L, Vaudry H & Kuhn J-M. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. Journal of Clinical Endocrinology and Metabolism 2006 91 1566-1572. (doi:10.1210/jc.2005-1453)
62. Louiset E, Duparc C, Groussin L, Laquerriere A, Kuhn JM, Reznik Y, Bertherat J & Lefebvre H. Abnormal sensitivity of cortisol secretion to glucagon in primary adrenal Cushing's syndrome. In Proceedings of the 13th Adrenal Cortex Conference, pp 52. June 11-14; Eds BP Schimmer, M Dufau & AC Brownie. San Francisco, USA, 2008.
63. McNicol AM, Richmond J & Charlton BG. A study of general innervation of the human adrenal cortex using PGP 9.5 immunohistochemistry. Acta Anatomica 1994 151 120-123. (doi:10.1159/000147652)
64. Van Aken MO, Pereira AM, Van Thiel SW, Van den Berg G, Frölich M, Veldhuis JD, Romijn JA & Roelfsema F. Irregular and frequent cortisol secretory episodes with preserved diurnal rhythmicity in primary adrenal Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 1570-1577. (doi:10.1210/jc.2004-1281)
65. Li Q, Johansson H, Kjellman M & Grimelius L. Neuroendocrine differentiation and nerves in human adrenal cortex and cortical lesions. Acta Pathologica Microbiologica et Immunologica Scandinavica 1998 106 807-817. (doi:10.1111/j.1699-0463.1998.tb00227.x)
66. Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP & Bornstein SR. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome. New England Journal of Medicine 1998 339 27-31. (doi:10.1056/NEJM199807023390105)
67. Merke DP, Bornstein SR, Braddock D & Chrousos GP. Adrenal lymphocytic infiltration and adrenocortical tumors in a patient with 21-hydroxylase deficiency. New England Journal of Medicine 1999 340 1121-1122. (doi:10.1056/NEJM199904083401416)
68. Wegienka LC, Komarmy LE, Wuepper KD & Forsham PH. Cushing's syndrome with adrenal medullary insufficiency and adrenal autoantibodies. Lancet 1966 1 741-743. (doi:10.1016/S0140-6736(66)90895-6)
69. Andrada JA, Murray FT, Andrada EC & Ezrin C. Cushing's syndrome and autoimmunity. Archives of Pathology and Laboratory Medicine 1979 103 244-246.
70. Aiba M, Iri H, Suzuki H, Kageyama K, Kawai T, Abe O, Murai M, Tazaki H & Saruta T. Numerous mast cells in an 11-deoxycorticosterone-producing adrenocortical tumor. Histologic evaluation of benignancy and comparison with mast cell distribution in adrenal glands and neoplastic counterparts of 67 surgical specimens. Archives of Pathology and Laboratory Medicine 1985 109 357-360.
71. Cartier D, Jégou S, Parmentier F, Lihrmann I, Louiset E, Kuhn JM, Bastard C, Plouin PF, Godin M, Vaudry H et al. Expression profile of serotonin 4 (5-HT4) receptors in adrenocortical aldosteroneproducing adenomas. European Journal of Endocrinology 2005 153 939-947. (doi:10.1530/eje.1.02051)
72. Louiset E, Isvi K, Gasc JM, Duparc C, Cauliez B, Laquerrière A, Kuhn JM & Lefebvre H. Ectopic expression of serotonin 7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocrine-Related Cancer 2008 15 1025-1034. (doi:10.1677/ERC-08-0085)
73. Dyduch G, Kaczmarczyk K & Okoń K. Mast cells and cancer: enemies or allies? Polish Journal of Pathology 2012 63 1-7.
74. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P & Salvetti A. Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism 2002 87 4961-4965. (doi:10.1210/jc.2001-011799)
75. Diaz-Cano SJ, De Miguel M, Blanes A, Galera H & Wolfe HJ. Contribution of the microvessel network to the clonal and kinetic profiles of adrenal cortical proliferative lesions. Human Pathology 2001 32 1232-1239. (doi:10.1053/hupa.2001.28949)
76. Magennis DP & McNicol AM. Vascular patterns in the normal and pathological human adrenal cortex. Virchows Archiv 1998 433 69-73. (doi:10.1007/s004280050218)
77. Boulkroun S, Samson-Couterie B, Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin PF, Lalli E, Jeunemaitre X, Benecke A et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010 56 885-892. (doi:10.1161/HYPERTENSIONAHA.110.158543)
78. Gunay LM, Bas KK & Uygur MC. Primary lipoma of the adrenal gland. American Surgeon 2011 77 1265-1267.
79. Babinska A, Nalecz A, Swiatkowska-Stodulska R & Sworczak K. Adrenal myelolipomas composed with adrenal nodular hyperplasia in the same gland. Polish Journal of Pathology 2012 63 45-48.
80. Cormio L, Ruutu M, Giardina C & Selvaggi FP. Combined adrenal adenoma and myelolipoma in a patient with Conn syndrome. Case report. Panminerva Medica 1992 34 209-212.
81. Inuzuka M, Tamura N, Sone M, Taura D, Sonoyama T, Honda K, Kojima K, Fukuda Y, Ueda Y, Yamashita Y et al. A case of myelolipoma with bilateral adrenal hyperaldosteronism cured after unilateral adrenalectomy. Internal Medicine 2012 51 479-485. (doi:10.2169/internalmedicine.51.5777)
82. Izumi M, Serizawa H, Iwaya K, Takeda K, Sasano H & Mukai K. A case of myxoid adrenocortical carcinoma with extensive lipomatous metaplasia. Archives of Pathology and Laboratory Medicine 2003 127 227-230.
83. Jung SI, Kim S-O, Kang TW, Kwon DD, Park K & Ryu SB. Bilateral adrenal myelolipoma associated with hyperaldosteronism: report of a case and review of the literature. Urology 2007 70 1223.e11-1223.e13. (doi:10.1016/j.urology.2007.09.046)
84. Hisamatsu H, Sakai H, Tsuda S, Shigematsu K & Kanetake H. Combined adrenal adenoma and myelolipoma in a patient withCushing's syndrome: case report and review of the literature. International Journal of Urology 2004 11 416-418. (doi:10.1111/j.1442-2042.2004.00815.x)
85. Lamas C, López LM, Lozano E, Atienzar M, Ruiz-Mondéjar R, Alfaro JJ & Botella F. Myelolipomatous adrenal masses causing Cushing's syndrome. Experimental and Clinical Endocrinology and Diabetes 2009 117 440-445. (doi:10.1055/s-0029-1202274)
86. Matsuda T, Abe H, Takase M, Arakawa A, Matsumoto T, Fujime M & Suda K. Case of combined adrenal cortical adenoma and myelolipoma. Pathology International 2004 54 725-729. (doi:10.1111/j.1440-1827.2004.01686.x)
87. Su H-C, Huang X, Dai J & Sun F-K. Adrenal myelolipoma associated with hyperandrogenemia. International Journal of Urology 2012 19 1026-1028. (doi:10.1111/j.1442-2042.2012.03100.x)
88. Luong KVQ, Nguyen LTH, van Nguyen S & Nguyen NT. Coexistence of the hypersecretion of catecholamine, adrenal cortical nodular hyperplasia, and nephrotic-range proteinuria of focal segmental scleronephrosis: is it fat-induced hypertension? International Journal of Clinical Medicine 2011 2 206-211. (doi:10.4236/ijcm.2011.23034)
89. Murray SA, Nickel BM & Gay VL. Gap junctions as modulators of adrenal cortical cell proliferation and steroidogenesis. Molecular and Cellular Endocrinology 2009 300 51-56. (doi:10.1016/j.mce.2008.09.027)
90. Neri G, Andreis PG, Prayer-Galetti T, Rossi GP, Malendowicz LK & Nussdorfer GG. Pituitary adenylate-cyclase activating peptide enhances aldosterone secretion of human adrenal gland: evidence for an indirect mechanism, probably involving the local release of catecholamines. Journal of Clinical Endocrinology and Metabolism 1996 81 169-173. (doi:10.1210/jc.81.1.169)
91. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L & Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002 40 897-902. (doi:10.1161/01.HYP.0000038478. 59760.41)
92. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ & Gordon RD. Factors affecting the aldosterone/renin ratio. Hormone and Metabolic Research 2012 44 170-176. (doi:10.1055/s-0031-1295460)
93. Hirata Y, Uchihashi M, Sueoka S, Matsukura S & Fujita T. Presence of ectopic β-adrenergic receptors on human adrenocortical cortisol-producing adenomas. Journal of Clinical Endocrinology and Metabolism 1981 53 953-957. (doi:10.1210/jcem-53-5-953)
94. Assie G, Louiset E, Sturm N, René-Corail F, Groussin L, Bertherat J, Thomas M, Lefebvre H, Feige JJ, Clauser E et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2010 95 E253-E262. (doi:10.1210/jc.2009-2281)
95. Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. Journal of Clinical Endocrinology and Metabolism 2005 90 1302-1310. (doi:10.1210/jc. 2004-1256)
96. Lacroix A, Tremblay J, Rousseau G, Bouvier M & Hamet P. Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome. New England Journal of Medicine 1997 337 1429-1434. (doi:10.1056/ NEJM199711133372004)
97. Mazzuco TL, Thomas M, Martinie M, Cherradi N, Sturm N, Feige JJ & Chabre O. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing β-blocker-sensitive Cushing's syndrome. Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 1452-1462. (doi:10.1590/S0004-27302007000900007)
98. Mircescu H, Jilwan J, N'Diaye N, Bourdeau I, Tremblay J, Hamet P & Lacroix A. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? Journal of Clinical Endocrinology and Metabolism 2000 85 3531-3536. (doi:10.1210/jc.85.10.3531)
99. Oki K, Yamane K, Nakanishi S, Nakashima R, Jitsuiki K & Kohno N. Improvement of hypercortisolism by β-blocker therapy in subclinical Cushing's syndrome associated with ACTHindependent macronodular adrenocortical hyperplasia. Endocrine 2009 36 372-376. (doi:10.1007/s12020-009-9246-3)
100. Mazzuco TL, Chaffanjon P, Martinie M, Sturm N & Chabre O. Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of β-blockade therapy and interest of unilateral adrenalectomy. Endocrine Journal 2009 56 867-877. (doi:10.1507/endocrj.K08E-370)
101. Oh HC, Koh JM, Kim MS, Park JY, Shong YK, Lee KU, Kim GS, Hong SJ, Koo HL & Kim WB. A case of ACTH-producing pheochromocytoma associated with pregnancy. Endocrine Journal 2003 50 739-744. (doi:10.1507/endocrj.50.739)
102. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E & Caron P. Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecological Endocrinology 2009 25 624-627. (doi:10.1080/09513590903015411)
103. Ballav C, Naziat A, Mihai R, Karavitaki N, Ansorge O & Grossman AB. Mini-review: pheochromocytomas causing the ectopic ACTH syndrome. Endocrine 2012 42 69-73. (doi:10.1007/s12020-012-9646-7)
104. Suda T, Tomori N, Yajima F, Odagiri E, Demura H & Shizume K. Characterization of immunoreactive corticotropin and corticotropin-releasing factor in human adrenal and ovarian tumours. Acta Endocrinologica 1986 111 546-552.
105. Lefebvre H, Duparc C, Chartrel N, Jegou S, Pellerin A, Laquerriere A, Ivell R, Vaudry H & Kuhn JM. Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 3035-3042. (doi:10.1210/jc.2002-030014)
106. Iwata M, Oki Y, Okazawa T, Ishizawa S, Taka C, Yamazaki K, Tobe K, Fukuoka J, Sasano H & Nishikawa T. A rare case of adrenocorticotropic hormone (ACTH)-independent macroadrenal hyperplasia showing ectopic production of ACTH. Internal Medicine 2012 51 2181-2187. (doi:10.2169/internalmedicine.51. 7547)
107. Lacaze-Masmonteil T, De Keyzer Y, Luton JP, Kahn A & Bertagna X. Characterization of proopiomelanocortin transcripts in human nonpituitary tissues. PNAS 1987 84 7261-7265. (doi:10.1073/pnas.84.20.7261)
108. Spera G, Di Benedetto E, Falaschi P, Fabbri A, Lauro G & Bolotti M. Immunohistochemical localization of β-endorphin in hyperplastic interstitial tissue of the human testis. Journal of Andrology 1988 9 78-81.
109. de Keyzer Y, Lenne F, Massias JF, Vieau D, Luton JP, Kahn A & Bertagna X. Pituitary-like proopiomelanocortin transcripts in human Leydig cell tumors. Journal of Clinical Investigation 1990 86 871-877. (doi:10.1172/ JCI114787)
110. Li HE, Hedger MP, Clements JA & Risbridger GP. Localization of immunoreactive β-endorphin and adrenocorticotropic hormone and pro-opiomelanocortin mRNA to rat testicular interstitial tissue macrophages. Biology of Reproduction 1991 45 282-289. (doi:10.1095/biolreprod45.2.282)
111. Davidoff MS, SchulzeW, Middendorff R & Holstein AF. The Leydig cell of the human testis - a new member of the diffuse neuroendocrine system. Cell and Tissue Research 1993 271 429-439. (doi:10.1007/BF02913725)
112. Claahsen-van der Grinten HL, Hermus AR & Otten BJ. Testicular adrenal rest tumours in congenital adrenal hyperplasia. International Journal of Pediatric Endocrinology 2009 2009 624823. (doi:10.1186/1687-9856-2009-624823)
113. Grazzini E, Boccara G, Joubert D, Trueba M, Durroux T, Guillon G, Gallo-Payet N, Chouinard L, Payet MD & Serradeil-LeGal C. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Advances in Experimental Medicine and Biology 1998 449 325-334.
114. Guillon G, Grazzini E, Andrez M, Breton C, Trueba M, Serradeil-LeGal C, Boccara G, Derick S, Chouinard L & Gallo-Payet N. Vasopressin: a potent autocrine/paracrine regulator of mammal adrenal functions. Endocrine Research 1998 24 703-710. (doi:10.3109/07435809809032672)
115. Kay J, Minkel DT, Gustafson AB, Skelton M, Cowley AW Jr & Wilson SD. Elevated plasma vasopressin (AVP) levels during resection of pheochromocytomas. Surgery 1986 100 1150-1153.
116. Boccara G, Mann C & Guillon G. Secretion of vasopressin from a human pheochromocytoma. Annals of Internal Medicine 1998 128 1049. (doi:10.7326/0003-4819-128-12-Part-1-199806150-00031)
117. Grazzini E, Breton C, Derick S, Andres M, Raufaste D, Rickwaert F, Boccara G, Colson P, Guérineau NC, Serradeil-LeGal C et al. Vasopressin receptors in human adrenal medulla and pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 1999 84 2195-2203. (doi:10.1210/jc.84.6.2195)
118. O'Brien T, Young WF Jr, Davila DG, Scheithauer BW, Kovacs K, Horvath E, Vale W & van Heerden JA. Cushing's syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma. Clinical Endocrinology 1992 37 460-467. (doi:10.1111/j.1365-2265.1992.tb02359.x)
119. Contesse V, Reznik Y, Duparc C, Perraudin V, Vaudry H, Kuhn JM & Lefebvre H. Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome. Endocrine Research 2002 28 787-791. (doi:10.1081/ERC-120017074)
120. Joubert M, Louiset E, Rego JL, Contesse V, Kong LC, Benhaim A, Mittre H, Lefebvre H, Reznik Y & REHOS Study Group. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors? Clinical Endocrinology 2008 68 692-699. (doi:10.1111/j.1365-2265. 2007.03106.x)
121. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J & Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clinical Endocrinology 2010 73 1-15. (doi:10.1111/j.1365-2265. 2009.03689.x)
122. Bourdeau I, D'Amour P, Hamet P, Boutin JM & Lacroix A. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 5534-5540. (doi:10.1210/jc.86.11.5534)
123. Daidoh H, Morita H, Hanafusa J, Mune T, Murase H, Sato M, Shibata T, Suwa T, Ishizuka T & Yasuda K. In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia. Clinical Endocrinology 1998 49 403-409. (doi:10.1046/j.1365-2265.1998.00490.x)
124. Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, Schiffrin EL & Hamet P. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with
125. Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E & Bertagna X. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2029-2035. (doi:10.1210/jc.83.6.2029)
126. Mune T, Murase H, Yamakita N, Fukuda T, Murayama M, Miura A, Suwa T, Hanafusa J, Daido H, Morita H et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2002 87 5706-5713. (doi:10.1210/jc.2002-020067)
127. Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Perraudin V, Bertherat J & Lefebvre H. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing's syndrome: molecular, immunohistochemical and pharmacological correlates. Journal of Endocrinology 2008 196 1-9. (doi:10.1677/JOE-07-0413)
128. Lee S, Hwang R, Lee J, Rhee Y, Kim DJ, Chung UI & Lim SK. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clinical Endocrinology 2005 63 625-630. (doi:10.1111/j.1365-2265.2005.02387.x)
129. Vezzosi D, Cartier D, Régnier C, Otal P, Bennet A, Parmentier F, Plantavid M, Lacroix A, Lefebvre H & Caron P. Familial adrenocorticotropin- independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. European Journal of Endocrinology 2007 156 21-31.(doi:10.1530/eje.1.02324)
130. Suzuki S, Uchida D, Koide H, Suyama K, Shibata T, Yoshida T, Tanaka T, Noguchi Y, Saito Y & Tatsuno I. A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosteroneproducing adenoma. Peptides 2008 29 2225-2231. (doi:10.1016/j. peptides.2008.09.001)
131. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F & Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. European Journal of Endocrinology 2009 160 443-451. (doi:10.1530/EJE-08-0711)
132. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H & Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochemical and Biophysical Research Communications 1993 192 553-560. (doi:10.1006/bbrc.1993.1451)
133. Takei Y, Hyodo S, Katafuchi T & Minamino N. Novel fish-derived adrenomedullin in mammals: structure and possible function. Peptides 2004 25 1643-1656. (doi:10.1016/j.peptides.2004.06.026)
134. Takahashi K, Morimoto R, Hirose T, Satoh F & Totsune K. Adrenomedullin 2/intermedin in the hypothalamo-pituitary- adrenal axis. Journal of Molecular Neuroscience 2011 43 182-192. (doi:10.1007/s12031-010-9413-2)
135. Andreis PG, Tortorella C, Mazzocchi G & Nussdorfer GG. Proadrenomedullin N-terminal 20 peptide inhibits aldosterone secretion of human adrenocortical and Conn's adenoma cells: comparison with adrenomedullin effect. Journal of Clinical Endocrinology and Metabolism 1998 83 253-257. (doi:10.1210/jc.83.1.253)
136. Belloni AS, Meneghelli V, Champion HC, Murray WA, Coy DH, Kadowitz PJ & Nussdorfer GG. Autoradiographic evidence that zona glomerulosa and capsular vessels of the human adrenal cortex are provided with different subtypes of adrenomedullin receptors. Peptides 1998 19 1581-1584. (doi:10.1016/S0196-9781(98)00111-9)
137. Satoh F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, Abe K, Miura Y & Mouri T. Immunoreactive adrenomedullin in human adrenal glands and adrenal tumors. Cancer Detection and Prevention 1997 21 51-54.
138. Rebuffat P, Malendowicz LK, Nussdorfer GG & Mazzocchi G. Stimulation of endogenous nitric oxide production is involved in the inhibitory effect of adrenomedullin on aldosterone secretion in the rat. Peptides 2001 22 923-926. (doi:10.1016/S0196-9781(01)00418-1)
139. Bodart V, Rainey WE, Fournier A, Ong H & De Léan A. The H295R human adrenocortical cell line contains functional atrial natriuretic peptide receptors that inhibit aldosterone biosynthesis. Molecular and Cellular Endocrinology 1996 118 137-144. (doi:10.1016/0303-7207(96)03776-8)
140. Kreklau EL, Carlson EJ & Drewett JG. Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation. Molecular and Cellular Endocrinology 1999 153 103-111. (doi:10.1016/S0303-7207(99)00075-1)
141. Forneris M, Gottardo L, Albertin G, Malendowicz LK & Nussdorfer GG. Expression and function of adrenomedullin and its receptors in Conn's adenoma cells. International Journal of Molecular Medicine 2001 8 675-679.
142. Morimoto R, Satoh F, Murakami O, Hirose T, Totsune K, Imai Y, Arai Y, Suzuki T, Sasano H, Ito S et al. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues. Journal of Endocrinology 2008 198 175-183. (doi:10.1677/JOE-08-0103)
143. Takahashi K, Satoh F, Sone M, Totsune K, Arihara Z, Noshiro T, Mouri T & Murakami O. Expression of adrenomedullin mRNA in adrenocortical tumors and secretion of adrenomedullin by cultured adrenocortical carcinoma cells. Peptides 1998 19 1719-1724. (doi:10.1016/S0196-9781(98)00128-4)
144. Letizia C, De Toma G, Cerci S, Massa R, Coassin S, Subioli S, Scuro L & De Ciocchis A. Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure. Blood Pressure 1998 7 19-23. (doi:10.1080/080370598437529)
145. Kita T, Tokashiki M & Kitamura K. Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. Hypertension Research 2010 33 374-379. (doi:10.1038/hr.2010.8)
146. Haidan A, Hilbers U, Bornstein SR & Ehrhart-Bornstein M. Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP). Peptides 1998 19 1511-1517. (doi:10.1016/S0196-9781(98)00115-6)
147. Nicol MR, Cobb VJ, Williams BC, Morley SD, Walker SW & Mason JI. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors. Journal of Molecular Endocrinology 2004 32 869-877. (doi:10.1677/jme.0.0320869)
148. Bodart V, Babinski K, Ong H & De Léan A. Comparative effect of pituitary adenylate cyclase-activating polypeptide on aldosterone secretion in normal bovine and human tumorous adrenal cells. Endocrinology 1997 138 566-573. (doi:10.1210/en.138.2.566)
149. Cugini P, Lucia P, Letizia C, Murano G & Pièche S. May a lymphocytic infiltration have a pathogenic role in an aldosterone-producing adrenal tumor? Medical Hypotheses 1985 17 33-38. (doi:10.1016/0306-9877(85) 90017-9)
150. Park YK, Kim YW, Kim JW, Choi YK, Ko YT, Ko SW & Yang MH. Bilateral primary pigmented nodular adrenocortical disease - a case of report describing a rare cause of Cushing's syndrome. Journal of Korean Medical Science 1994 9 450-457.
151. Willenberg HS, Päth G, Vögeli TA, Scherbaum WA & Bornstein SR. Role of interleukin-6 in stress response in normal and tumorous adrenal cells and during chronic inflammation. Annals of the New York Academy of Sciences 2002 966 304-314. (doi:10.1111/j.1749-6632.2002.tb04230.x)
152. Akatsu T, Kameyama K, Araki K, Ashizawa T, Wakabayashi G & Kitajima M. Functioning adrenocortical oncocytoma: the first documented case producing interleukin-6 and review of the literature. Journal of Endocrinological Investigation 2008 31 68-73.
153. Contesse V, Lefebvre H, Lenglet S, Kuhn JM, Delarue C & Vaudry H. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Canadian Journal of Physiology and Pharmacology 2000 78 967-983. (doi:10.1139/y00-098)
154. Lefebvre H, Contesse V, Delarue C, Legrand A, Kuhn JM, Vaudry H & Wolf LM. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. Journal of Clinical Endocrinology and Metabolism 1995 80 504-507. (doi:10.1210/jc.80.2.504)
155. Ahmed AH, Calvird M, Gordon RD, Taylor PJ, Ward G, Pimenta E, Young R & Stowasser M. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. Journal of Clinical Endocrinology and Metabolism 2011 96 1039-1045. (doi:10.1210/jc.2010-2603)
156. Grunenwald S, Mazzuco TL, Mermejo, LM, Bourdeau I & Lacroix A. In vivo systematic screening for hormone receptors in primary aldosteronism reveals frequent aberrant hormone responsiveness. In ENDO., p S1540. San Diego, California, USA, 2010.
157. Lampron A, Bourdeau I, Oble S, Godbout A, Schürch W, Arjane P, Hamet P & Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for glucosedependent insulinotropic peptide in a patient with an aldosteronoma. Journal of Clinical Endocrinology and Metabolism 2009 94 750-756. (doi:10.1210/jc.2008-1340)
158. Williams TA, Monticone S, Morello F, Liew CC, Mengozzi G, Pilon C, Asioli S, Sapino A, Veglio F & Mulatero P. Teratocarcinomaderived growth factor-1 is upregulated in aldosterone-producing adenomasandincreases aldosterone secretion andinhibits apoptosis in vitro. Hypertension 2010 55 1468-1475. (doi:10.1161/HYPERTENSIONAHA.110.150318)
159. Ye P, Mariniello B, Mantero F, Shibata H & RaineyWE. G-proteincoupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. Journal of Endocrinology 2007 195 39-48. (doi:10.1677/JOE-07-0037)
160. Lefebvre H, Cartier D, Duparc C, Lihrmann I, Contesse V, Delarue C, Godin M, Fischmeister R, Vaudry H & Kuhn JM. Characterization of serotonin (4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 2002 87 1211-1216. (doi:10.1210/jc.87.3.1211)
161. Gross MD, Grekin RJ, Gniadek TC & Villareal JZ. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. New England Journal of Medicine 1981 305 181-185. (doi:10.1056/NEJM198107233050401)
162. Mantero F, Rocco S, Opocher G, Armanini D, Boscaro M & D'Agostino D. Effect of ketanserin in primary aldosteronism. Journal of Cardiovascular Pharmacology 1985 7 (Suppl 7) S172-S175. (doi:10.1097/00005344-198500077-00048)
163. Cartier D, Lihrmann I, Parmentier F, Bastard C, Bertherat J, Caron P, Kuhn JM, Lacroix A, Tabarin A, Young J et al. Overexpression of serotonin 4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 248-254. (doi:10.1210/jc.2002-021107)
164. Dall'Asta C, Ballarè E, Mantovani G, Ambrosi B, Spada A, Barbetta L, Colombo P, Travaglini P, Loli P & Beck-Peccoz P. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Hormone and Metabolic Research 2004 36 578-583. (doi:10.1055/s-2004-825797)
165. Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. Journal of Clinical Endocrinology and Metabolism 2003 88 230-237. (doi:10.1210/jc.2002-020621)
166. Miyamura N, Tsutsumi A, Senokuchi H, Nakamaru K, Kawashima J, Sakai K, Taguchi T, Tokunaga H, Nishida K, Uehara M et al. A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocrine Journal 2003 50 333-340. (doi:10.1507/endocrj.50.333)
167. Reznik Y, Lefebvre H, Rohmer V, Charbonnel B, Tabarin A, Rodien P, Lecomte P, Bardet S, Coffin C, Mahoudeau J et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clinical Endocrinology 2004 61 311-319. (doi:10.1111/j.1365-2265.2004.02048.x)
168. Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Barrande G, Bertherat J, Vaudry H & Lefebvre H. Expression of serotonin 7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 4578-4586. (doi:10.1210/jc.2006-0538)
169. Lacroix A, Bolté E, Tremblay J, Dupré J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome. New England Journal of Medicine 1992 327 974-980. (doi:10.1056/ NEJM199210013271402)
170. Louiset E, Cartier D, Contesse V, Duparc C, Lihrmann I, Young J, Bertherat J, Reznik Y, Kuhn JM, Laquerrière A et al. Paradoxical inhibitory effect of serotonin on cortisol production from adrenocortical lesions causing Cushing's syndrome. Endocrine Research 2004 30 951-954. (doi:10.1081/ERC-200044170)
171. Lampron A, Bourdeau I, Hamet P, Tremblay J & Lacroix A.Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 3611-3618. (doi:10.1210/jc.2006-0221)
172. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH & Kebebew E. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery 2008 143 841-846 (discussion 846). (doi:10.1001/archsurg.143.9.841)
173. Frishman WH & Grewall P. Serotonin and the heart. Annals of Medicine 2000 32 195-209. (doi:10.3109/07853890008998827)
174. Rossi G, Albertin G, Belloni A, Zanin L, Biasolo MA, Prayer- Galetti T, Bader M, Nussdorfer GG, Palù G & Pessina AC. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. Journal of Clinical Investigation 1994 94 1226-1234. (doi:10.1172/JCI117440)
175. Rossi GP, Albertin G, Franchin E, Sacchetto A, Cesari M, Palù G & Pessina AC. Expression of the endothelin-converting enzyme gene in human tissues. Biochemical and Biophysical Research Communications 1995 211 249-253. (doi:10.1006/bbrc.1995.1803)
176. Rossi GP, Andreis PG, Neri G, Tortorella C, Pelizzo MR, Sacchetto A & Nussdorfer GG. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenasedependent signaling pathways. Journal of Investigative Medicine 2000 48 343-350.
177. Egidy G, Baviera E, Ciuffo G, Corvol P & Pinet F. Localization of the endothelin system in aldosterone-producing adenomas. Hypertension 2001 38 1137-1142. (doi:10.1161/hy1001.092652)
178. Morello F, Schiavone D, Mengozzi G, Bertello C, Liew CC, Bisbocci D, Mulatero P & Veglio F. Adrenal endothelin-1 levels are not associated with aldosterone secretion in primary aldosteronism. European Journal of Endocrinology 2009 160 453-458. (doi:10.1530/EJE-08-0828)
179. Zeng Z, Tang X, Yang D, Li H, Zhang R, Zeng Q, Li M, Chen J, Lu Z, Demura H et al. Immunoreactive endothelin-1 and its receptors in human adrenal tissues. Journal of Cardiovascular Pharmacology 1998 31 (Suppl 1) S212-S214. (doi:10.1097/00005344-199800001-00059)
180. Burton TJ, Cope G, Wang J, Sim JC, Azizan EA, O'Shaughnessy KM & Brown MJ. Expression of the epithelial Na(C) channel and other components of an aldosterone response pathway in human adrenocortical cells. European Journal of Pharmacology 2009 613 176-181. (doi:10.1016/j.ejphar.2009.04.005)
181. Burton TJ, Azizan EAB & Brown MJ. Investigating the function of an aldosterone response pathway in primary human adrenocortical cells obtained from Conn's and phaeochromocytoma patients. European Journal of Pharmacology 2011 657 184-189. (doi:10.1016/j.ejphar.2011.01.051)
182. Gummow BM, Scheys JO, Cancelli VR & Hammer GD. Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Molecular Endocrinology 2006 20 2711-2723. (doi:10.1210/me.2005- 0461)
183. Louiset E, Stratakis CA, Perraudin V, Griffin KJ, Libé R, Cabrol S, Fève B, Young J, Groussin L, Bertherat J et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. Journal of Clinical Endocrinology and Metabolism 2009 94 2406-2413. (doi:10.1210/jc.2009- 0031)
184. Paust HJ, Loeper S, Else T, Bamberger AM, Papadopoulos G, Pankoke D, Saeger W & Bamberger CM. Expression of the glucocorticoid receptor in the human adrenal cortex. Experimental and Clinical Endocrinology & Diabetes 2006 114 6-10. (doi:10.1055/s-2005-873007)
185. Reincke M, Beuschlein F, Menig G, Hofmockel G, Arlt W, Lehmann R, Karl M & Allolio B. Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex. Journal of Endocrinology 1998 156 415-423. (doi:10.1677/joe.0.1560415)
186. Tacon LJ, Soon PS, Gill AJ, Chou AS, Clarkson A, Botling J, Stalberg PL, Skogseid BM, Robinson BG, Sidhu SB et al. The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 4591-4599. (doi:10.1210/jc.2009-0546)
187. Kontula K, Pomoell UM, Gunsalus GL & Pelkonen R. Glucocorticoid receptors and responsiveness of normal and neoplastic human adrenal cortex. Journal of Clinical Endocrinology and Metabolism 1985 60 283-289. (doi:10.1210/jcem-60-2-283)
188. Bourdeau I, Lacroix A, Schürch W, Caron P, Antakly T & Stratakis CA. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. Journal of Clinical Endocrinology and Metabolism 2003 88 3931-3937. (doi:10.1210/jc.2002-022001)
189. Damjanovic SS,Antic JA, Ilic BB, Cokic BB, IvovicM,Ognjanovic SI, Isailovic TV, Popovic BM, Bozic IB, Tatic S et al. Glucocorticoid receptor and molecular chaperones in the pathogenesis of adrenal incidentalomas: potential role of reduced sensitivity to glucocorticoids. Molecular Medicine 2013 18 1456-1465. (doi:10.2119/molmed.2012.00261)
190. Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A & Stratakis CA. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 2930-2937. (doi:10.1210/jc.2009- 0516)
191. Feltus FA, Cote S, Simard J, Gingras S, Kovacs WJ, Nicholson WE, Clark BJ & Melner MH. Glucocorticoids enhance activation of the human type II 3b-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. Journal of Steroid Biochemistry and Molecular Biology 2002 82 55-63. (doi:10.1016/S0960-0760(02) 00147-4)
192. Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman JL, Nieman LK, Chrousos GP & Papanicolaou DA. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Annals of Internal Medicine 1999 131 585-591. (doi:10.7326/0003-4819-131-8-199910190- 00006)
193. Louiset E, Gobet F, Libé R, Horvath A, Renouf S, Cariou J, Rothenbuhler A, Bertherat J, Clauser E, Grise P et al. ACTHindependent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. Journal of Clinical Endocrinology and Metabolism 2010 95 18-24. (doi:10.1210/jc.2009-0881)
194. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, René-Corail F, Stergiopoulos S, Bourdeau I et al. Mutations in regulatory subunit type 1A of cyclic adenosine 50-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. Journal of Clinical Endocrinology and Metabolism 2009 94 2085-2091. (doi:10.1210/jc.2008-2333)
195. Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, René-Corail F, Faucz FR et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-a of protein kinase A (PRKAR1A): an update. Human Mutation 2010 31 369-379. (doi:10.1002/humu.21178)
196. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-Dejean C et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Research 2003 63 5308-5319.
197. Oda N, Takeda Y, Zhu A, Usukura M, Yoneda T, Takata H & Mabuchi H. Pathophysiological roles of the adrenal renin- angiotensin system in patients with primary aldosteronism. Hypertension Research 2006 29 9-14. (doi:10.1291/hypres.29.9)
198. Wu Z, Ni D, Yan Y, Li J,Wang B, Ouyang J, Zhang G, Ma X, Li H & Zhang X. Expression of angiotensin II receptors in aldosteroneproducing adenoma of the adrenal gland and their clinical significance. Journal of Huazhong University of Science and Technology-Medical Sciences 2010 30 486-489. (doi:10.1007/s11596-010-0454-0)
199. Wen M-J, Lin Y-F & Chen J-S. Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression. International Journal of Urology 2008 15 540-542. (doi:10.1111/j.1442-2042.2008. 02038.x)
200. Nguyen G & Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Current Opinion in Pharmacology 2008 8 127-132. (doi:10.1016/j.coph. 2007.12.009)
201. Nguyen G. Renin, (pro)renin and receptor: an update. Clinical Science 2011 120 169-178. (doi:10.1042/CS20100432)
202. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libé R, René-Corail F, Audebourg A, Vacher-Lavenu MC et al. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. Journal of Clinical Endocrinology and Metabolism 2011 96 E419-E426. (doi:10.1210/jc.2010-1885)
203. El Wakil A & Lalli E. The Wnt/β-catenin pathway in adrenocortical development and cancer. Molecular and Cellular Endocrinology 2011 332 32-37. (doi:10.1016/j.mce.2010.11.014)
204. Berthon A, Martinez A, Bertherat J & Val P. Wnt/β-catenin signalling in adrenal physiology and tumour development. Molecular and Cellular Endocrinology 2012 351 87-95. (doi:10.1016/j.mce.2011.09.009)
205. DeBaun M & Horst J. Beckwith-Wiedemann syndrome. In Adrenocortical Carcinoma, pp 227-234. Hammer GD & Else T. New-York: Springer, 2011.
206. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. American Journal of Pathology 2012 181 1017-1033. (doi:10.1016/j.ajpath.2012.05.026)
207. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F & Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 1444-1453. (doi:10.1210/jc.78.6. 1444)
208. Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y & Gicquel C. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 1999 23 23-32. (doi:10.1677/jme.0.0230023)
209. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, de Joussineau C, Batisse-Lignier M, Lefrançois-Martinez A-M, Bertherat J et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS ONE 2012 7 e44171. (doi:10.1371/journal.pone.0044171)
210. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E & Hammer GD. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2009 94 204-212. (doi:10.1210/jc.2008- 1456)
211. Arola J, Liu J, Heikkilä P, Voutilainen R & Kahri A. Expression of inhibin a in the human adrenal gland and adrenocortical tumors. Endocrine Research 1998 24 865-867. (doi:10.3109/07435809809032699)
212. Munro LM, Kennedy A & McNicol AM. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. Journal of Endocrinology 1999 161 341-347. (doi:10.1677/joe.0.1610341)
213. Vänttinen T, Liu J, Kuulasmaa T, Kivinen P & Voutilainen R. Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. Journal of Endocrinology 2003 178 479-489. (doi:10.1677/joe.0. 1780479)
214. Wang EY, Ma EY & Woodruff TK. Activin signal transduction in the fetal rat adrenal gland and in human H295R cells. Journal of Endocrinology 2003 178 137-148. (doi:10.1677/joe.0.1780137)
215. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H & Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. PNAS 1994 91 8817-8821. (doi:10.1073/pnas.91.19.8817)
216. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 2005 90 1819-1829. (doi:10.1210/jc.2004-1075)
217. Hofland J, Timmerman MA, De Herder WW, Van Schaik RHN, De Krijger RR & De Jong FH. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Clinical Endocrinology 2006 65 792-799. (doi:10.1111/j.1365-2265.2006.02668.x)
218. Cho EY & Ahn GH. Immunoexpression of inhibin a-subunit in adrenal neoplasms. Applied Immunohistochemistry & Molecular Morphology 2001 9 222-228. (doi:10.1097/00022744-200109000-00005)
219. Fragoso MC, Kohek MB, Martin RM, Latronico AC, Lucon AM, Zerbini MC, Longui CA, Mendonca BB & Domenice S. An inhibin B and estrogen-secreting adrenocortical carcinoma leading to selective FSH suppression. Hormone Research 2007 67 7-11. (doi:10.1159/000095806)
220. Kuhn JM, Lefebvre H, Duparc C, Pellerin A, Luton JP & Strauch G. Cosecretion of estrogen and inhibin B by a feminizing adrenocortical adenoma: impact on gonadotropin secretion. Journal of Clinical Endocrinology and Metabolism 2002 87 2367-2375. (doi:10.1210/jc.87.5.2367)
221. Nishi Y, Haji M, Takayanagi R, Yanase T, Ikuyama S & Nawata H. In vivo and in vitro evidence for the production of inhibin-like immunoreactivity in human adrenocortical adenomas and normal adrenal glands: relatively high secretion from adenomas manifesting Cushing's syndrome. European Journal of Endocrinology 1995 132 292-299. (doi:10.1530/eje.0.1320292)
222. Adashi EY, Resnick CE, Hernandez ER, May JV, Purchio AF & Twardzik DR. Ovarian transforming growth factor-b (TGFb): cellular site(s), and mechanism(s) of action. Molecular and Cellular Endocrinology 1989 61 247-256. (doi:10.1016/0303-7207(89)90136-6)
223. Benahmed M, Morera AM, Ghiglieri C, Tabone E, Menezo Y, Hendrick JC & Franchimont P. Transforming growth factor-b(s) in the ovary. Annals of the New York Academy of Sciences 1993 687 13-19. (doi:10.1111/j.1749-6632.1993.tb43848. x)
224. Feige JJ & Baird A. Growth factor regulation of adrenal cortex growth and function. Progress in Growth Factor Research 1991 3 103-113. (doi:10.1016/S0955-2235(05)80002-X)
225. Boccuzzi A, Terzolo M, Cappia S, De Giuli P, De Risi C, Leonardo E, Bovio S, Borriero M, Paccotti P & Angeli A. Different immunohistochemical patterns of TGF-b1 expression in benign and malignant adrenocortical tumours. Clinical Endocrinology 1999 50 801-808. (doi:10.1046/j.1365-2265.1999.00683.x)
226. Lebrethon MC, Jaillard C, Naville D, Bégeot M & Saez JM. Effects of transforming growth factor-b1 on human adrenocortical fasciculata-reticularis cell differentiated functions. Journal of Clinical Endocrinology and Metabolism 1994 79 1033-1039. (doi:10.1210/jc.79.4.1033)
227. Parker CR Jr, Stankovic AK, Harlin C & Carden L. Adrenocorticotropin interferes with transforming growth factor-β-induced growth inhibition of neocortical cells from the human fetal adrenal gland. Journal of Clinical Endocrinology and Metabolism 1992 75 1519-1521. (doi:10.1210/jc.75.6.1519)
228. Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S & Yoshino G. Restoration of transforming growth factor-b type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line. Hormone and Metabolic Research 2006 38 159-166. (doi:10.1055/s-2006-925185)
229. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H, Perlemoine K, Martinez A & Bertherat J. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF β-stimulated apoptosis in adrenocortical cells. Cancer Research 2009 69 7278-7284. (doi:10.1158/0008-5472.CAN-09-1601)
230. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes and Development 1996 10 1580-1594. (doi:10.1101/gad.10.13.1580)
231. Von Bubnoff A & Cho KW. Intracellular BMP signaling regulation in vertebrates: pathway or network? Developmental Biology 2001 239 1-14. (doi:10.1006/dbio.2001.0388)
232. Johnsen IK & Beuschlein F. Role of bone morphogenetic proteins in adrenal physiology and disease. Journal of Molecular Endocrinology 2010 44 203-211. (doi:10.1677/JME-10-0001)
233. Huber K, Franke A, Brühl B, Krispin S, Ernsberger U, Schober A, von Bohlen und Halbach O, Rohrer H, Kalcheim C & Unsicker K. Persistent expression of BMP-4 in embryonic chick adrenal cortical cells and its role in chromaffin cell development. Neural Development 2008 3 28. (doi:10.1186/1749- 8104-3-28)
234. Kano Y, Otsuka F, Takeda M, Suzuki J, Inagaki K, Miyoshi T, Miyamoto M, Otani H, Ogura T & Makino H. Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells. Endocrinology 2005 146 5332-5340. (doi:10.1210/en.2005-0474)
235. Inagaki K, Otsuka F, Suzuki J, Kano Y, Takeda M, Miyoshi T, Otani H, Mimura Y, Ogura T & Makino H. Involvement of bone morphogenetic protein-6 in differential regulation of aldosterone production by angiotensin II and potassium in human adrenocortical cells. Endocrinology 2006 147 2681-2689. (doi:10.1210/en.2005-1250)
236. Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, Kano Y, Goto J, Ogura T & Makino H. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008 149 2816-2825. (doi:10.1210/en.2007-1476)
237. Johnsen IK, Kappler R, Auernhammer CJ & Beuschlein F. Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Research 2009 69 5784-5792. (doi:10.1158/0008-5472.CAN-08-4428)
238. Caroccia B, Fassina A, Seccia TM, Recarti C, Petrelli L, Belloni AS, Pelizzo MR & Rossi GP. Isolation of human adrenocortical aldosterone-producing cells by a novel immunomagnetic beads method. Endocrinology 2010 151 1375-1380. (doi:10.1210/en.2009-1243)
239. Hatskelzon L, Dalal BI, Shalev A, Robertson C & Gerrard JM. Wide distribution of granulophysin epitopes in granules of human tissues. Laboratory Investigation 1993 68 509-519.
240. Miura W, Mizunashi K, Kimura N, Koide Y, Noshiro T, Miura Y, Furukawa Y & Nagura H. Expression of stanniocalcin in zona glomerulosa and medulla of normal human adrenal glands, and some adrenal tumors and cell lines. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2000 108 367-372. (doi:10.1034/j.1600-0463.2000.d01-70.x)
241. Alsabeh R, Mazoujian G, Goates J, Medeiros LJ & Weiss LM. Adrenal cortical tumors clinically mimicking pheochromocytoma. American Journal of Clinical Pathology 1995 104 382-390.
242. Miettinen M. Neuroendocrine differentiation in adrenocortical carcinoma. New immunohistochemical findings supported by electron microscopy. Laboratory Investigation 1992 66 169-174.
243. Haak HR & Fleuren GJ. Neuroendocrine differentiation of adrenocortical tumors. Cancer 1995 75 860-864. (doi:10.1002/1097-0142(19950201) 75:3!860::AID-CNCR2820750318O3.0.CO;2-G)
244. Shigematsu K, Nishida N, Sakai H, Igawa T, Toriyama K, Nakatani A, Takahara O & Kawai K. Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression. European Journal of Endocrinology 2009 161 939-945. (doi:10.1530/EJE-09-0596)
245. Lachenmayer A, Lichtenauer UD, Cox T, Schott M, Malendowicz LK, Goretzki PE, Cupisti K, Scherbaum WA, Bornstein SR & Willenberg HS. Nestin as a marker in the classification of adrenocortical tumors. Hormone and Metabolic Research 2009 41 397-401. (doi:10.1055/s-0029-1202788)
246. Horvath A, Mathyakina L, Vong Q, Baxendale V, Pang AL,Chan WY & Stratakis CA. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. Journal of Clinical Endocrinology and Metabolism 2006 91 584-596. (doi:10.1210/jc.2005-1301)
247. Stratakis CA, Carney JA, Kirschner LS, Willenberg HS, Brauer S, Ehrhart-Bornstein M & Bornstein SR. Synaptophysin immunoreactivity in primary pigmented nodular adrenocortical disease: neuroendocrine properties of tumors associated with Carney complex. Journal of Clinical Endocrinology and Metabolism 1999 84 1122-1128. (doi:10.1210/jc.84.3.1122)
248. Bornstein SR, Ehrhart M & Scherbaum WA. Ultrastructural evidence for cortico-chromaffin hybrid cells in rat adrenals? Endocrinology 1991 129 1113-1115. (doi:10.1210/endo-129-2-1113)
249. Middendorff R, Davidoff M & Holstein AF. Neuroendocrine marker substances in human Leydig cells - changes by disturbances of testicular function. Andrologia 1993 25 257-262. (doi:10.1111/j.1439-0272.1993.tb02722.x)
250. Nicholson HD, Swann RW, Burford GD, Wathes DC, Porter DG & Pickering BT. Identification of oxytocin and vasopressin in the testis and in adrenal tissue. Regulatory Peptides 1984 8 141-146. (doi:10.1016/0167-0115(84)90169-1)
251. Saez JM. Leydig cells: endocrine, paracrine, and autocrine regulation. Endocrine Reviews 1994 15 574-626.
252. Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S & Yamamoto Y. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku Journal of Experimental Medicine 2009 217 193-201. (doi:10.1620/tjem.217.193)
253. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y et al. Nf1-dependent tumors require a microenvironment containing Nf1C/K and c-kit-dependent bone marrow. Cell 2008 135 437-448. (doi:10.1016/j.cell. 2008.08.041)
254. Marner L, Gillings N, Madsen K, Erritzoe D, Baaré WFC, Svarer C, Hasselbalch SG & Knudsen GM. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. NeuroImage 2010 50 855-861. (doi:10.1016/j. neuroimage.2010.01.054)
255. Assie G, Giordano TJ & Bertherat J. Gene expression profiling in adrenocortical neoplasia. Molecular and Cellular Endocrinology 2012 351 111-117. (doi:10.1016/j.mce.2011.09.044)
256. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 2009 27 1108-1115. (doi:10.1200/JCO.2008.18.5678)
257. Charlton BG, Nkomazana OF, McGadey J & Neal DE. A preliminary study of acetylcholinesterase-positive innervation in the human adrenal cortex. Journal of Anatomy 1991 176 99-104.
258. Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM & Vaudry H. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. Journal of Clinical Endocrinology and Metabolism 1993 76 1522-1528. (doi:10.1210/jc.76.6.1522)
259. Fraser R, Connell JM, Inglis G, Kenyon CJ & Tree M. The role of dopamine in the control of corticosteroid secretion and metabolism. Journal of Steroid Biochemistry 1989 32 217-222. (doi:10.1016/0022-4731(89)90168-4)
260. Charlton BG, McGadey J, Russell D & Neal DE. Noradrenergic innervation of the human adrenal cortex as revealed by dopamine-β- hydroxylase immunohistochemistry. Journal of Anatomy 1992 180 501-506.
261. Bornstein SR, Haidan A & Ehrhart-Bornstein M. Cellular communication in the neuro-adrenocortical axis: role of vasoactive intestinal polypeptide (VIP). Endocrine Research 1996 22 819-829. (doi:10.1080/07435809609043781)
262. Conconi MT, Spinazzi R & Nussdorfer GG. Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland. International Review of Cytology 2006 249 1-51. (doi:10.1016/S0074-7696(06) 49001-X)